1119 related articles for article (PubMed ID: 22791289)
61. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
[TBL] [Abstract][Full Text] [Related]
62. A new standard of care in newly diagnosed multiple myeloma.
Richardson PG
Lancet; 2010 Dec; 376(9758):2043-4. PubMed ID: 21146204
[No Abstract] [Full Text] [Related]
63. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
[TBL] [Abstract][Full Text] [Related]
64. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Moreau P; Hulin C; Macro M; Caillot D; Chaleteix C; Roussel M; Garderet L; Royer B; Brechignac S; Tiab M; Puyade M; Escoffre M; Stoppa AM; Facon T; Pegourie B; Chaoui D; Jaccard A; Slama B; Marit G; Laribi K; Godmer P; Luycx O; Eisenmann JC; Allangba O; Dib M; Araujo C; Fontan J; Belhadj K; Wetterwald M; Dorvaux V; Fermand JP; Rodon P; Kolb B; Glaisner S; Malfuson JV; Lenain P; Biron L; Planche L; Caillon H; Avet-Loiseau H; Dejoie T; Attal M
Blood; 2016 May; 127(21):2569-74. PubMed ID: 27002117
[TBL] [Abstract][Full Text] [Related]
65. Treatment of newly diagnosed myeloma.
Palumbo A; Rajkumar SV
Leukemia; 2009 Mar; 23(3):449-56. PubMed ID: 19005483
[TBL] [Abstract][Full Text] [Related]
66. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
67. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Pineda-Roman M; Zangari M; van Rhee F; Anaissie E; Szymonifka J; Hoering A; Petty N; Crowley J; Shaughnessy J; Epstein J; Barlogie B
Leukemia; 2008 Jul; 22(7):1419-27. PubMed ID: 18432260
[TBL] [Abstract][Full Text] [Related]
68. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
Terragna C; Remondini D; Martello M; Zamagni E; Pantani L; Patriarca F; Pezzi A; Levi G; Offidani M; Proserpio I; De Sabbata G; Tacchetti P; Cangialosi C; Ciambelli F; Viganò CV; Dico FA; Santacroce B; Borsi E; Brioli A; Marzocchi G; Castellani G; Martinelli G; Palumbo A; Cavo M
Oncotarget; 2016 Mar; 7(9):9666-79. PubMed ID: 26575327
[TBL] [Abstract][Full Text] [Related]
69. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
70. Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Togano T; Andoh S; Komuro M; Mitsui Y; Itoi S; Hirai R; Nakamura M; Tanimura A; Sekine R; Takeshita M; Miwa A; Hagiwara S
Intern Med; 2022 Nov; 61(22):3329-3334. PubMed ID: 35466165
[TBL] [Abstract][Full Text] [Related]
71. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
72. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
[TBL] [Abstract][Full Text] [Related]
73. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
[TBL] [Abstract][Full Text] [Related]
74. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
[TBL] [Abstract][Full Text] [Related]
75. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Takashima S; Miyamoto T; Kadowaki M; Ito Y; Aoki T; Takase K; Shima T; Yoshimoto G; Kato K; Muta T; Shiratsuchi M; Takenaka K; Iwasaki H; Teshima T; Kamimura T; Akashi K
Int J Hematol; 2014 Aug; 100(2):159-64. PubMed ID: 24928523
[TBL] [Abstract][Full Text] [Related]
76. Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
Chen RA; Tu Y; Cao Y; Liu L; Liang Y
J Int Med Res; 2011; 39(5):1975-84. PubMed ID: 22118002
[TBL] [Abstract][Full Text] [Related]
77. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
[TBL] [Abstract][Full Text] [Related]
78. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.
Horvath N; Spencer A; Kenealy M; Joshua D; Campbell PJ; Lee JJ; Hou J; Qiu L; Kalff A; Khong T; Londhe A; Siggins S; van Kooten Losio M; Eisbacher M; Prince HM
Leuk Lymphoma; 2019 Sep; 60(9):2122-2133. PubMed ID: 30777794
[TBL] [Abstract][Full Text] [Related]
79. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
80. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
